US Pharma MarketingThe post Viatris reports positive topline data from trial of VR-205 for IgAN appeared first on Clinical Trials Arena.
Viatris reports positive topline data from trial of VR-205 for IgAN
Viatris has reported positive topline data from a Phase III trial assessing VR-205, a targeted-release budesonide, also known as Nefecon, in Japanese adults with primary IgAN who are at risk for end-stage renal disease. VR-205 reduced UPCR by 33.75% at nine months compared to baseline. No participants advanced to dialysis, kidney transplant or severe renal impairment by the end of the trial. Credit: sasirin pamai/Shutterstock.com. Viatris has reported positive topline data from a Phase III trial assessing VR-205, a targeted-release budesonide, also known as Nefecon, in Japanese adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for end-stage…
Viatris has reported positive topline data from a Phase III trial assessing VR-205, a targeted-release budesonide, also known as Nefecon, in Japanese adults with primary IgAN who are at risk for end-stage renal disease.
Source: Clinical Trials Arena